Days earlier, Novo Nordisk cut its sales and profit forecast for first time since the launch of Wegovy four years ago.
Wegovy-maker Novo Nordisk has pushed out CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.
Novo Nordisk announced the decision on Friday.
Days earlier, Novo Nordisk cut its sales and profit forecast for the first time since the launch of Wegovy four years ago, though Jorgensen had…
Continue Reading
News Source: www.aljazeera.com

Leave a Reply